title: Giant cell arteritis.
abstract: OBJECTIVE
  Giant cell arteritis is an important cause of blindness in patients over 60 years of age. We attempt to identify the important clinical aspects in the diagnosis and management of this disorder, so that treatment may be instituted expeditiously to limit visual loss.
  
  
  RESULTS
  In addition, we identify current areas of standards in the investigation and treatment of patients with suspected giant cell arteritis.
  
  
  CONCLUSIONS
  We review some newer treatment possibilities, based on recently proposed immunologic models of giant cell arteritis, that may lead to newer treatment modalities.
authors.affiliation: Department of Ophthalmology, University of Auckland, Auckland, New Zealand.
authors.forename: Helen V
authors.initials: HV
authors.lastname: Danesh-Meyer
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Savino
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D001706:Biopsy; D004334:Drug Administration Schedule; D013700:Giant Cell Arteritis / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011379:Prognosis; D014786:Vision Disorders / Q000209:etiology
chemical_list: D000305:Adrenal Cortex Hormones; D010975:Platelet Aggregation Inhibitors; D008775:Methylprednisolone; D008727:Methotrexate